Development of novel targeted therapies in the treatment of malignant glioma.
Rich
Jeremy N
JN
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. rich0001@mc.duke.edu
Bigner
Darell D
DD
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D002453:Cell Cycle / Q000235:genetics* / Q000502:physiology; D002986:Clinical Trials as Topic; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D008967:Molecular Biology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000502:physiology
D000903:Antibiotics, Antineoplastic; D016159:Tumor Suppressor Protein p53; D004815:Epidermal Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor